A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

PHASE2CompletedINTERVENTIONAL
Enrollment

273

Participants

Timeline

Start Date

August 11, 2015

Primary Completion Date

September 26, 2017

Study Completion Date

September 26, 2017

Conditions
Choroidal Neovascularization
Interventions
DRUG

Faricimab

Faricimab will be administered as per the regimen specified in the individual arm.

DRUG

Ranibizumab

Ranibizumab will be administered as per the regimen specified in the individual arm.

DRUG

Sham Procedure

The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in treatment arm D at applicable visits to maintain masking.

Trial Locations (52)

11021

Long Is. Vitreoretinal Consult, Great Neck

11563

Opthalmic Consultants of LI, Lynbrook

12159

The Retina Consultants, Slingerlands

14620

Retina Assoc of Western NY, Rochester

19107

Mid Atlantic Retina, Philadelphia

20815

Retina Group of Washington, Chevy Chase

21204

National Retina Institute, Towson

22903

Univ of Virginia Ophthalmology, Charlottesville

28210

Char Eye Ear &Throat Assoc, Charlotte

28803

Western Carolina Retinal Associate PA, Asheville

29169

Palmetto Retina Center, West Columbia

30060

Georgia Retina PC, Marietta

30909

Southeast Retina Center, Augusta

32308

Southern Vitreoretinal Assoc, Tallahassee

32806

Central Florida Retina, Orlando

32901

Florida Eye Associates, Melbourne

33410

Retina Care Specialists, Palm Beach Gardens

33711

Retina Vitreous Assoc of FL, St. Petersburg

33907

Retina Health Center, Fort Myers

33912

National Ophthalmic Research Institute, Fort Myers

37203

Tennessee Retina PC., Nashville

37421

Southeastern Retina Associates Chattanooga, Chattanooga

38138

Charles Retina Institute, Germantown

42001

Paducah Retinal Center, Paducah

43212

OSU Eye Physicians & Surgeons, Columbus

46290

Midwest Eye Institute Northside, Indianapolis

55435

Vitreoretinal Surgery, Edina

76087

Strategic Clinical Research Group, LLC, Willow Park

77030

Retina Consultants of Houston, Houston

78705

Austin Retina Associates, Austin

Retina Research Center, Austin

79606

W Texas Retina Consultants PA, Abilene

80401

Colorado Retina Associates, PC, Golden

80909

Retina Consultants of Southern, Colorado Springs

84107

Retina Associates of Utah, Salt Lake City

85020

Associated Retina Consultants, Phoenix

85053

Retinal Consultants of Arizona, Phoenix

87102

Eye Associates of New Mexico, Albuquerque

90211

Retina-Vitreous Associates Medical Group, Beverly Hills

90603

American Institute of Research, Whittier

91436

The Retina Partners, Encino

92064

Retina Consultants, San Diego, Poway

92705

Orange County Retina Med Group, Santa Ana

93309

California Retina Consultants, Bakersfield

94598

Bay Area Retina Associates, Walnut Creek

97221

Retina Northwest, Portland

97401

Oregon Retina, LLP, Eugene

97504

Oregon Retina institute, Medford

99204

Spokane Eye Clinical Research, Spokane

06518

New England Retina Associates, Hamden

01605

Vitreo-Retinal Associates, PC, Worcester

08755

Retina Associates of NJ, Toms River

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02484690 - A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) | Biotech Hunter | Biotech Hunter